Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CJM112 in inadequately controlled moderate to severe asthma
2017-000205-21Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing CJM112 with Placebo (2 arms). Primary endpoint: Change from baseline FEV1 in mL. Started Nov 2017; status: completed.
02
Drugs
CJM112
03
Conditions
asthma
Beyond the preview
Go deeper on 2017-000205-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000205-21.